121 related articles for article (PubMed ID: 11270226)
1. Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.
Crul M; van den Bongard HJ; Tibben MM; van Tellingen O; Sava G; Schellens JH; Beijnen JH
Fresenius J Anal Chem; 2001 Mar; 369(5):442-5. PubMed ID: 11270226
[TBL] [Abstract][Full Text] [Related]
2. Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry.
Brouwers EE; Tibben MM; Rosing H; Schellens JH; Beijnen JH
Rapid Commun Mass Spectrom; 2007; 21(9):1521-30. PubMed ID: 17410551
[TBL] [Abstract][Full Text] [Related]
3. A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Flaibani A; Bult A; Beijnen JH
Int J Pharm; 2002 Nov; 248(1-2):239-46. PubMed ID: 12429477
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Sava G; Perbellini A; Flaibani A; van Steenbergen MJ; Talsma H; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
Int J Pharm; 2002 Nov; 248(1-2):247-59. PubMed ID: 12429478
[TBL] [Abstract][Full Text] [Related]
5. Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.
Cocchietto M; Sava G
Pharmacol Toxicol; 2000 Nov; 87(5):193-7. PubMed ID: 11129497
[TBL] [Abstract][Full Text] [Related]
6. Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.
Cocchietto M; Salerno G; Alessio E; Mestroni G; Sava G
Anticancer Res; 2000; 20(1A):197-202. PubMed ID: 10769655
[TBL] [Abstract][Full Text] [Related]
7. Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Picotti F; Flaibani A; Bult A; Beijnen JH
J Pharm Biomed Anal; 2003 Feb; 31(2):215-28. PubMed ID: 12609661
[TBL] [Abstract][Full Text] [Related]
8. Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.
Bergamo A; Zorzet S; Cocchietto M; Carotenuto ME; Magnarin M; Sava G
Anticancer Res; 2001; 21(3B):1893-8. PubMed ID: 11497274
[TBL] [Abstract][Full Text] [Related]
9. Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy beagle dogs.
Sava G; Cocchietto M
In Vivo; 2000; 14(6):741-4. PubMed ID: 11204491
[TBL] [Abstract][Full Text] [Related]
10. Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
Brescacin L; Masi A; Sava G; Bergamo A
J Biol Inorg Chem; 2015 Oct; 20(7):1163-73. PubMed ID: 26369538
[TBL] [Abstract][Full Text] [Related]
11. Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.
Novohradský V; Bergamo A; Cocchietto M; Zajac J; Brabec V; Mestroni G; Sava G
Dalton Trans; 2015 Jan; 44(4):1905-13. PubMed ID: 25489765
[TBL] [Abstract][Full Text] [Related]
12. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.
Messori L; Orioli P; Vullo D; Alessio E; Iengo E
Eur J Biochem; 2000 Feb; 267(4):1206-13. PubMed ID: 10672032
[TBL] [Abstract][Full Text] [Related]
13. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
14. Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells.
Frausin F; Cocchietto M; Bergamo A; Scarcia V; Furlani A; Sava G
Cancer Chemother Pharmacol; 2002 Nov; 50(5):405-11. PubMed ID: 12439599
[TBL] [Abstract][Full Text] [Related]
15. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.
Sava G; Bergamo A; Zorzet S; Gava B; Casarsa C; Cocchietto M; Furlani A; Scarcia V; Serli B; Iengo E; Alessio E; Mestroni G
Eur J Cancer; 2002 Feb; 38(3):427-35. PubMed ID: 11818210
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
[TBL] [Abstract][Full Text] [Related]
17. Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Bult A; Beijnen JH
J Pharm Biomed Anal; 2002 Nov; 30(4):1287-96. PubMed ID: 12408919
[TBL] [Abstract][Full Text] [Related]
18. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.
Brouwers EE; Tibben MM; Joerger M; van Tellingen O; Rosing H; Schellens JH; Beijnen JH
Anal Bioanal Chem; 2005 Aug; 382(7):1484-90. PubMed ID: 15952001
[TBL] [Abstract][Full Text] [Related]
19. Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration.
Cocchietto M; Zorzet S; Sorc A; Sava G
Invest New Drugs; 2003 Feb; 21(1):55-62. PubMed ID: 12795530
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous observation of the metabolism of cisplatin and NAMI-A in human plasma in vitro by SEC-ICP-AES.
Sooriyaarachchi M; Wedding JL; Harris HH; Gailer J
J Biol Inorg Chem; 2014 Aug; 19(6):1049-53. PubMed ID: 24458238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]